Project 4: Neoadjuvant Clinical Trial with Pembrolizumab for Locally Advanaced Squamous Cell Carcinoma (SCC)

NIH RePORTER · NIH · P50 · $381,600 · view on reporter.nih.gov ↗

Abstract

This is a phase II single-arm neoadjuvant pembrolizumab trial in patients with PD-1 naïve resectable locally advanced SCC.

Key facts

NIH application ID: 11175542
Project number: 5P50CA254865-04
Recipient: UNIVERSITY OF PITTSBURGH AT PITTSBURGH
Principal Investigator: John Munn Kirkwood
Activity code: P50
Funding institute: NIH
Fiscal year: 2024
Award amount: $381,600
Award type: 5
Project period: 2024-07-01 → 2026-06-30